Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $9.12 Consensus Target Price from Brokerages

Key Points

• Autolus Therapeutics PLC has received an average recommendation of "Buy" from five research firms, with a target price set at $9.12.
• Significant investment activity includes a 2,891.7% increase in ownership by Bank of America Corp DE, now holding over $2.2 million worth of shares.
• The company reported quarterly earnings of ($0.18) per share, which beat expectations and was accompanied by revenue of $13.5 million.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been assigned an average recommendation of "Buy" from the five analysts that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.12.

AUTL has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, July 21st.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock traded down $0.08 on Wednesday, hitting $1.31. The stock had a trading volume of 1,915,405 shares, compared to its average volume of 2,122,679. The stock has a 50 day moving average of $2.05 and a 200 day moving average of $1.83. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The firm has a market capitalization of $347.31 million, a P/E ratio of -1.55 and a beta of 1.87.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. Equities analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AUTL. Armistice Capital LLC boosted its holdings in shares of Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after buying an additional 1,800,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Autolus Therapeutics by 6.9% during the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock worth $41,992,000 after buying an additional 1,746,020 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock worth $2,223,000 after buying an additional 942,540 shares in the last quarter. TFG Asset Management GP Ltd boosted its holdings in shares of Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock worth $21,660,000 after buying an additional 900,000 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock worth $3,885,000 after buying an additional 790,437 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.